The importance of mitochondria in the tumourigenic phenotype: Gliomas as the paradigm (Review)

International Journal of Molecular Medicine

Volumn 27, Issue 2, 2011, Pages 159-171

  Liang, Bertrand C ^a,b   Grootveld, Martin ^b  

^a Pfenex Inc   (United States)

^b UNIVERSITY OF BOLTON   (United Kingdom)

Author keywords

Amplification; Astrocytoma; Mitochondrial DNA; Review; Unknown sign

Indexed keywords

3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; ADENOSINE TRIPHOSPHATE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETHYLNITROSOUREA; ETOPOSIDE; GLUTATHIONE; HYDROXYUREA; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; MANGANESE SUPEROXIDE DISMUTASE; METHOTREXATE; MITOCHONDRIAL DNA; PREDNISONE; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE 5; UNCLASSIFIED DRUG; VINCRISTINE; ZIDOVUDINE;

APOPTOSIS; BRAIN MITOCHONDRION; BRAIN TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENICITY; CD4 LYMPHOCYTE COUNT; CELL ORGANELLE; CITRIC ACID CYCLE; COPY NUMBER VARIATION; DNA SEQUENCE; DRUG EFFICACY; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOTYPE; GLIOBLASTOMA; GLIOMA; GLYCOLYSIS; HUMAN; LOW DRUG DOSE; LYMPHOMA; MEDICAL DECISION MAKING; NEUROBLASTOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA;

ANIMALS; DNA, MITOCHONDRIAL; GLIOMA; HUMANS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; PHENOTYPE;

EID: 78751657666     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2010.579     Document Type: Review

References (171)

1. Neyns B, D'Haeseleer M, Rogiers A, et al: The role of cytotoxic drugs in the treatment of central nervous system gliomas. Acta Neurol Belg 110: 1-14, 2010.
2. Ruiz J and Lesser GJ: Low-grade gliomas. Curr Treat Options Oncol 10: 231-242, 2009.
3. Cavalli LR and Liang BC: Mutagenesis, tumorigenicity, and apoptosis: are the mitochondria involved? Mutat Res 398: 19-26, 1998.
4. Liang BC, Meltzer PS, Guan XY and Trent JM: Gene amplification elucidated by combined chromosomal microdissection and comparative genomic hybridization. Cancer Genet Cytogenet 80: 55-59, 1995.
5. Liang BC: Direct isolation of variably amplified cDNAs from human tumour cell lines. Int J Oncol 7: 611-615, 1995.
6. Firkin FC and Clark-Walker GD: Abnormal mitochondrial DNA in acute leukaemia and lymphoma. Br J Haematol 43: 201-206, 1979. (Pubitemid 10243279)
7. Gianni AM, Dalla-Favera R and Polli E: Restriction enzyme analysis of human leukemic mitochondrial DNA. Leuk Res 4: 155-160, 1980.
8. Liang BC and Hays L: Mitochondrial DNA copy number changes in human gliomas. Cancer Lett 105: 167-173, 1996.
9. Dmitrenko V, Shostak K, Boyko O, et al: Reduction of the transcription level of the mitochondrial genome in human glioblastoma. Cancer Lett 218: 99-107, 2005. (Pubitemid 40082706)
10. Kirches E, Krause G, Warich-Kirches M, et al: High frequency of mitochondrial DNA mutations in glioblastoma multiforme identified by direct sequence comparison to blood samples. Int J Cancer 93: 534-538, 2001. (Pubitemid 32701412)
11. Vega A, Salas A, Gamborino E, Sobrido MJ, Macaulay V and Carracedo A: mtDNA mutations in tumors of the central nervous system reflect the neutral evolution of mtDNA in populations. Oncogene 23: 1314-1320, 2004.
12. Montanini L, Regna-Gladin C, Eoli M, et al: Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas. J Neurooncol 74: 87-89, 2005.
13. Clayton DA and Vinograd J: Circular dimer and catenate forms of mitochondrial DNA in human leukaemic leucocytes. Nature 216: 652-657, 1967.
14. Clayton DA and Smith CA: Complex mitochondrial DNA. Int Rev Exp Pathol 14: 1-67, 1975.
15. Ragnini A and Fukuhara H: Genetic instability of an oligomycin resistance mutation in yeast is associated with an amplification of a mitochondrial DNA segment. Nucleic Acids Res 17: 6927-6937, 1989.
16. Traven A, Wong JM, Xu D, Sopta M and Ingles CJ: Interorganellar communication. Altered nuclear gene expression profiles in a yeast mitochondrial DNA mutant. J Biol Chem 276: 4020-4027, 2001. (Pubitemid 33645868)
17. Penta JS, Johnson FM, Wachsman JT and Copeland WC: Mitochondrial DNA in human malignancy. Mutat Res 488: 119-133, 2001.
18. Carew JS and Huang P: Mitochondrial defects in cancer. Mol Cancer 1: 9, 2002.
19. Beheshti B, Braude I, Marrano P, Thorner P, Zielenska M and Squire JA: Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia 5: 53-62, 2003.
20. Haugen DR, Fluge O, Reigstad LJ, Varhaug JE and Lillehaug JR: Increased expression of genes encoding mitochondrial proteins in papillary thyroid carcinomas. Thyroid 13: 613-620, 2003.
21. Jia L, Liu KZ, Newland AC, Mantsch HH and Kelsey SM: Pgp-positive leukaemic cells have increased mtDNA but no increased rate of proliferation. Br J Haematol 107: 861-869, 1999.
22. Tarantul VZ, Nikolaev AI, Martynenko A, Hannig H, Hunsmann G and Bodemer W: Differential gene expression in B-cell non-Hodgkin's lymphoma of SIV-infected monkey. AIDS Res Hum Retroviruses 16: 173-179, 2000.
23. Nikolaev AI, Martynenko AV, Kalmyrzaev BB, et al: [Amplification of transcription of separate mitochondrial genes in human and monkey B-cell non-Hodgkin's lymphoma]. Mol Biol (Mosk) 35: 120-127, 2001 (In Russian).
24. Nenasheva VV, Nikolaev AI, Dubovaia VI, et al: [Analysis of expression of a series of lymphoma-specific genes in human fibroblasts immortalized by SV40 virus]. Mol Biol (Mosk) 38: 265-275, 2004 (In Russian).
25. Dani MA, Dani SU, Lima SP, et al: Less DeltamtDNA4977 than normal in various types of tumors suggests that cancer cells are essentially free of this mutation. Genet Mol Res 3: 395-409, 2004.
26. Kiebish MA and Seyfried TN: Absence of pathogenic mitochondrial DNA mutations in mouse brain tumors. BMC Cancer 5: 102, 2005.
27. Kamalidehghan B, Houshmand M, Panahi MS, Abbaszadegan MR, Ismail P and Shiroudi MB: Tumoral cell mtDNA approximately 8.9 kb deletion is more common than other deletions in gastric cancer. Arch Med Res 37: 848-853, 2006. (Pubitemid 44333144)
28. Poetsch M, Dittberner T, Petersmann A and Woenckhaus C: Mitochondrial DNA instability in malignant melanoma of the skin is mostly restricted to nodular and metastatic stages. Melanoma Res 14: 501-508, 2004. (Pubitemid 40221141)
29. Chung KL, Shim S, Kim J and Song E: Analysis of mitochondrial DNA mutation in hepatoma. J Biochem 33: 417-421, 2000.
30. Polyak K, Li Y, Zhu H, et al: Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 20: 291-293, 1998.
31. Dai JG, Xiao YB, Min JX, Zhang GQ, Yao K and Zhou RJ: Mitochondrial DNA 4977 BP deletion mutations in lung carcinoma. Indian J Cancer 43: 20-25, 2006.
32. Zhu W, Qin W, Bradley P, Wessel A, Puckett CL and Sauter ER: Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid. Carcinogenesis 26: 145-152, 2005.
33. Guo XG and Guo QN: Mutations in the mitochondrial DNA D-loop region occur frequently in human osteosarcoma. Cancer Lett 239: 151-155, 2006.
34. Pejovic T, Ladner D, Intengan M, et al: Somatic D-loop mitochondrial DNA mutations are frequent in uterine serous carcinoma. Eur J Cancer 40: 2519-2524, 2004.
35. Maximo V, Soares P, Seruca R, Rocha AS, Castro P and Sobrinho-Simoes M: Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma. Genes Chromosomes Cancer 32: 136-143, 2001.
36. Liu VW, Shi HH, Cheung AN, et al: High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res 61: 5998-6001, 2001.
37. Wang Y, Liu VW, Xue WC, Tsang PC, Cheung AN and Ngan HY: The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: a quantitative study using laser-captured microdissected tissues. Gynecol Oncol 98: 104-110, 2005.
38. Tan DJ, Bai RK and Wong LJ: Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res 62: 972-976, 2002. (Pubitemid 34160271)
39. Lievre A, Blons H, Houllier AM, et al: Clinicopathological significance of mitochondrial D-loop mutations in head and neck carcinoma. Br J Cancer 94: 692-697, 2006.
40. Duncan EL, Perrem K and Reddel RR: Identification of a novel human mitochondrial D-loop RNA species which exhibits upregulated expression following cellular immortalization. Biochem Biophys Res Commun 276: 439-446, 2000.
41. Zhou S, Kachhap S and Singh KK: Mitochondrial impairment in p53-deficient human cancer cells. Mutagenesis 18: 287-292, 2003.
42. Gochhait S, Bhatt A, Sharma S, Singh YP, Gupta P and Bamezai RN: Concomitant presence of mutations in mitochondrial genome and p53 in cancer development - a study in north Indian sporadic breast and esophageal cancer patients. Int J Cancer 123: 2580-2586, 2008.
43. Jakupciak JP, Wang W, Markowitz ME, et al: Mitochondrial DNA as a cancer biomarker. J Mol Diagn 7: 258-267, 2005.
44. Ivanova R, Lepage V, Loste MN, et al: Mitochondrial DNA sequence variation in human leukemic cells. Int J Cancer 76: 495-498, 1998.
45. Campbell CL and Thorsness PE: Escape of mitochondrial DNA to the nucleus in yme1 yeast is mediated by vacuolar-dependent turnover of abnormal mitochondrial compartments. J Cell Sci 111: 2455-2464, 1998.
46. Thorsness PE and Weber ER: Escape and migration of nucleic acids between chloroplasts, mitochondria, and the nucleus. Int Rev Cytol 165: 207-234, 1996.
47. Shay JW and Werbin H: New evidence for the insertion of mitochondrial DNA into the human genome: significance for cancer and aging. Mutat Res 275: 227-235, 1992.
48. Corral M, Paris B, Baffet G, et al: Increased level of the mitochondrial ND5 transcript in chemically induced rat hepatomas. Exp Cell Res 184: 158-166, 1989.
49. - petites in Saccharomyces cerevisiae stimulates recombination. Gene 83: 25-38, 1989.
50. Liang BC: Evidence for association of mitochondrial DNA sequence amplification and nuclear localization in human lowgrade gliomas. Mutat Res 354: 27-33, 1996.
51. Guescini M, Genedani S, Stocchi V and Agnati LF: Astrocytes and glioblastoma cells release exosomes carrying mtDNA. J Neural Transm 117: 1-4, 2010.
52. Czarnecka AM, Felice VD, Zummo G and Cappello F: Cancer as a 'Mitochondriopathy'. J Cancer Mol 3: 71-79, 2007.
53. Bianchi NO, Bianchi MS and Richard SM: Mitochondrial genome instability in human cancers. Mutat Res 488: 9-23, 2001.
54. Yamauchi A: Rate of gene transfer from mitochondria to nucleus: effects of cytoplasmic inheritance system and intensity of intracellular competition. Genetics 171: 1387-1396, 2005.
55. Sorenson MD and Fleischer RC: Multiple independent transpositions of mitochondrial DNA control region sequences to the nucleus. Proc Natl Acad Sci USA 93: 15239-15243, 1996.
56. Hirano T, Shiraishi K, Adachi K, Miura S, Watanabe H and Utiyama H: Co-localization of mitochondrial and double minute DNA in the nuclei of HL-60 cells but not normal cells. Mutat Res 425: 195-204, 1999. (Pubitemid 29182653)
57. Hadler HI, Devadas K and Mahalingam R: Selected nuclear LINE elements with mitochondrial-DNA-like inserts are more plentiful and mobile in tumor than in normal tissue of mouse and rat. J Cell Biochem 68: 100-109, 1998.
58. Ricchetti M, Tekaia F and Dujon B: Continued colonization of the human genome by mitochondrial DNA. PLoS Biol 2: E273, 2004.
59. Eppert K, Scherer SW, Ozcelik H, et al: MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86: 543-552, 1996.
60. Borensztajn K, Chafa O, Alhenc-Gelas M, et al: Characterization of two novel splice site mutations in human factor VII gene causing severe plasma factor VII deficiency and bleeding diathesis. Br J Haematol 117: 168-171, 2002.
61. Turner C, Killoran C, Thomas NS, et al: Human genetic disease caused by de novo mitochondrial-nuclear DNA transfer. Hum Genet 112: 303-309, 2003.
62. Copeland WC, Wachsman JT, Johnson FM and Penta JS: Mitochondrial DNA alterations in cancer. Cancer Invest 20: 557-569, 2002.
63. Modica-Napolitano JS and Singh KK: Mitochondria as targets for detection and treatment of cancer. Expert Rev Mol Med 4: 1-19, 2002.
64. Saffroy R, Chiappini F, Debuire B and Lemoine A: Emerging concepts in the analysis of mitochondrial genome instability. Curr Genomics 5: 309-325, 2004.
65. Chatterjee A, Mambo E and Sidransky D: Mitochondrial DNA mutations in human cancer. Oncogene 25: 4663-4674, 2006. (Pubitemid 44187616)
66. Paul MK and Mukhopadhyay AK: Cancer-the mitochondrial connection. Biologia 62: 371-380, 2007.
67. Ray AJ, Turner R, Nikaido O, Rees JL and Birch-Machin MA: The spectrum of mitochondrial DNA deletions is a ubiquitous marker of ultraviolet radiation exposure in human skin. J Invest Dermatol 115: 674-679, 2000.
68. Cai Q, Shu XO, Wen W, et al: Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Breast Cancer Res 6: R647-R655, 2004.
69. Darvishi K, Sharma S, Bhat AK, Rai E and Bamezai RN: Mitochondrial DNA G10398A polymorphism imparts maternal Haplogroup N a risk for breast and esophageal cancer. Cancer Lett 249: 249-255, 2007.
70. Canter JA, Kallianpur AR, Parl FF and Millikan RC: Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res 65: 8028-8033, 2005.
71. Jiang WW, Masayesva B, Zahurak M, et al: Increased mitochondrial DNA content in saliva associated with head and neck cancer. Clin Cancer Res 11: 2486-2491, 2005.
72. Jiang WW, Rosenbaum E, Mambo E, et al: Decreased mitochondrial DNA content in posttreatment salivary rinses from head and neck cancer patients. Clin Cancer Res 12: 1564-1569, 2006.
73. Cavalli LR, Varella-Garcia M and Liang BC: Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ 8: 1189-1198, 1997.
74. Nass MM: Differential effects of ethidium bromide on mitochondrial and nuclear DNA synthesis in vivo in cultured mammalian cells. Exp Cell Res 72: 211-222, 1972.
75. Nikiforov MA, Hagen K, Ossovskaya VS, et al: p53 modulation of anchorage independent growth and experimental metastasis. Oncogene 13: 1709-1719, 1996.
76. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773, 2009.
77. Hartmann C, Meyer J, Balss J, et al: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118: 469-474, 2009.
78. Hao HX, Khalimonchuk O, Schraders M, et al: SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325: 1139-1142, 2009.
79. Burnichon N, Briere JJ, Libe R, et al: SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 19: 3011-3020, 2010.
80. Hayashi J, Tagashira Y, Watanabe T and Yoshida MC: Effect of mitochondrial DNA transmitted cytoplasmically from non-tumorigenic to tumorigenic rat cells on the phenotypic expression of tumorigenicity. Cancer Res 44: 3957-3960, 1984.
81. Griguer CE, Oliva CR, Gobin E, et al: CD133 is a marker of bioenergetic stress in human glioma. PLoS One 3: e3655, 2008.
82. Hayashi J, Werbin H and Shay JW: Effects of normal human fibroblast mitochondrial DNA on segregation of HeLaTG mitochondrial DNA and on tumorigenicity of HeLaTG cells. Cancer Res 46: 4001-4006, 1986.
83. Hayashi J, Takemitsu M and Nonaka I: Recovery of the missing tumorigenicity in mitochondrial DNA-less HeLa cells by introduction of mitochondrial DNA from normal human cells. Somat Cell Mol Genet 18: 123-129, 1992.
84. Zinkewich-Peotti K, Parent M and Morais R: On the tumorigenicity of mitochondrial DNA-depleted avian cells. Cancer Lett 59: 119-124, 1991.
85. Xue L, Fletcher GC and Tolkovsky AM: Mitochondria are selectively eliminated from eukaryotic cells after blockade of caspases during apoptosis. Curr Biol 11: 361-365, 2001. (Pubitemid 32200740)
86. Dong X, Ghoshal K, Majumder S, Yadav SP and Jacob ST: Mitochondrial transcription factor A and its downstream targets are up-regulated in a rat hepatoma. J Biol Chem 277: 43309-43318, 2002.
87. Grandemange S, Seyer P, Carazo A, et al: Stimulation of mitochondrial activity by p43 overexpression induces human dermal fibroblast transformation. Cancer Res 65: 4282-4291, 2005.
88. Ambrosone CB, Freudenheim JL, Thompson PA, et al: Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res 59: 602-606, 1999.
89. Roy D, Felty Q, Narayan S and Jayakar P: Signature of mitochondria of steroidal hormones-dependent normal and cancer cells: potential molecular targets for cancer therapy. Front Biosci 12: 154-173, 2007.
90. Palomares T, Bilbao P, del Olmo M, Castro B, Calle Y and Alonso-Varona A: In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma. Melanoma Res 9: 233-242, 1999.
91. Ohnami S, Matsumoto N, Nakano M, et al: Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity. Cancer Res 59: 5565-5571, 1999.
92. Weinberg F, Hamanaka R, Wheaton WW, et al: Mitochondrial metabolism and ROS generation are essential for K-ras-mediated tumorigenicity. Proc Natl Acad Sci USA 107: 8788-8793, 2010.
93. Mills KI, Woodgate LJ, Gilkes AF, et al: Inhibition of mitochondrial function in HL60 cells is associated with an increased apoptosis and expression of CD14. Biochem Biophys Res Commun 263: 294-300, 1999.
94. Magda D, Lecane P, Prescott J, et al: mtDNA depletion confers specific gene expression profiles in human cells grown in culture and in xenograft. BMC Genomics 9: 521, 2008.
95. Felty Q and Roy D: Estrogen, mitochondria, and growth of cancer and non-cancer cells. J Carcinog 4: 1, 2005.
96. Akimoto M, Niikura M, Ichikawa M, et al: Nuclear DNA but not mtDNA controls tumor phenotypes in mouse cells. Biochem Biophys Res Commun 327: 1028-1035, 2005. (Pubitemid 40137971)
97. Li M, Wang J, Ng SS, et al: The four-and-a-half-LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities. Glia 56: 1328-1338, 2008.
98. Ismail A and Bateman A: Expression of TBX2 promotes anchorage-independent growth and survival in the p53-negative SW13 adrenocortical carcinoma. Cancer Lett 278: 230-240, 2009.
99. Yu M, Shi Y, Wei X, et al: Depletion of mitochondrial DNA by ethidium bromide treatment inhibits the proliferation and tumorigenesis of T47D human breast cancer cells. Toxicol Lett 170: 83-93, 2007. (Pubitemid 46498907)
100. Liang BC: Increased expression but not sensitivity to Fas/CD95 in glioblastoma cells depleted of mitochondrial DNA. Exp Ther Med 1: 1049-1055, 2010.
101. Biswas G, Anandatheerthavarada HK and Avadhani NG: Mechanism of mitochondrial stress-induced resistance to apoptosis in mitochondrial DNA-depleted C2C12 myocytes. Cell Death Differ 12: 266-278, 2005. (Pubitemid 40360950)
102. Amuthan G, Biswas G, Zhang SY, Klein-Szanto A, Vijayasarathy C and Avadhani NG: Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. EMBO J 20: 1910-1920, 2001.
103. Butow RA and Avadhani NG: Mitochondrial signaling: the retrograde response. Mol Cell 14: 1-15, 2004.
104. Del Giudice L, Massardo DR, Pontieri P and Wolf K: Interaction between yeast mitochondrial and nuclear genomes: null alleles of RTG genes affect resistance to the alkaloid lycorine in unknown sign0 petites of Saccharomyces cerevisiae. Gene 354: 9-14, 2005.
105. Liang BC, Miller L and Weller A: Ethyl-nitrosourea transformed astrocytes exhibit mitochondrial membrane hyperpolarization and constrained apoptosis. Apoptosis 4: 89-97, 1999. (Pubitemid 29378792)
106. Hiraga S, Arita N, Ohnishi T, et al: Transformation of type 1 astrocytes with N-ethyl-N-nitrosourea: establishment of an in vitro system and the role of the p53 gene. Glia 13: 51-63, 1995.
107. Fantin VR, St-Pierre J and Leder P: Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9: 425-434, 2006.
108. Halabe Bucay A: The biological significance of cancer: mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment. Med Hypotheses 69: 826-828, 2007.
109. Matarrese P, Testa U, Cauda R, Vella S, Gambardella L and Malorni W: Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis. Biochem J 355: 587-595, 2001. (Pubitemid 32434074)
110. Liang BC and Ullyatt E: Increased sensitivity to cis-diammine- dichloroplatinum induced apoptosis with mitochondrial DNA depletion. Cell Death Differ 5: 694-701, 1998.
111. Bouayadi K, Hoffmann JS, Fons P, Tiraby M, Reynes JP and Cazaux C: Overexpression of DNA polymerase beta sensitizes mammalian cells to 2′,3′-deoxycytidine and 3′-azido-3′- deoxythymidine. Cancer Res 57: 110-116, 1997. (Pubitemid 27020338)
112. Ullyatt E and Liang BC: 2′,3′-Dideoxycytidine is a potent inducer of apoptosis in glioblastoma cells. Anticancer Res 18: 1859-1863, 1998.
113. Burger AM, Kaur G, Alley MC, et al: Tyrphostin AG17, [(3,5- Di-tert-butyl-4-hydroxybenzylidene)- malononitrile], inhibits cell growth by disrupting mitochondria. Cancer Res 55: 2794-2799, 1995.
114. Ara G and Teicher B: Relationship of cellular energy parameters to cytotoxicity for AG-17, lonidamine and cyclocreatine in four human tumour cell lines. Int J Oncol 8: 865-873, 1996.
115. Liang BC and Ullyatt E: Chemosensitization of glioblastoma cells to bis-dichloroethyl-nitrosourea with tyrphostin AG17. Clin Cancer Res 4: 773-781, 1998.
116. Lena A, Rechichi M, Salvetti A, Bartoli B et al: Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells. J Transl Med 7: 13, 2009.
117. Griguer CE, Oliva CR, Gillespie GY, Gobin E, Marcorelles P and Yancey Gillespie G: Pharmacologic manipulations of mitochondrial membrane potential (DeltaPsim) selectively in glioma cells. J Neurooncol 81: 9-20, 2007. (Pubitemid 44963984)
118. Higgins SC and Pilkington GJ: The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma. Anticancer Res 30: 391-397, 2010.
119. Perez-Ortiz JM, Tranque P, Burgos M, Vaquero CF and Llopis J: Glitazones induce astroglioma cell death by releasing reactive oxygen species from mitochondria: modulation of cytotoxicity by nitric oxide. Mol Pharmacol 72: 407-417, 2007.
120. Erguven M, Yazihan N, Aktas E, et al: Carvedilol in glioma treatment alone and with imatinib in vitro. Int J Oncol 36: 857-866, 2010.
121. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K and Kishimoto T: Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 85: 757-764, 1995.
122. Westendorf JJ, Lammert JM and Jelinek DF: Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 85: 3566-3576, 1995.
123. Lund KC, Peterson LL and Wallace KB: Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. Antimicrob Agents Chemother 51: 2531-2539, 2007.
124. Louat T, Servant L, Rols MP, et al: Antitumor activity of 2′,3′- dideoxycytidine nucleotide analog against tumors up-regulating DNA polymerase beta. Mol Pharmacol 60: 553-558, 2001.
125. Hentosh P and Tibudan M: 2-Chloro-2′-deoxyadenosine, an antileukemic drug, has an early effect on cellular mitochondrial function. Mol Pharmacol 51: 613-619, 1997. (Pubitemid 27172988)
126. Bjerke M, Franco M, Johansson M, Balzarini J and Karlsson A: Increased mitochondrial DNA copy-number in CEM cells resistant to delayed toxicity of 2′,3′-dideoxycytidine. Biochem Pharmacol 75: 1313-1321, 2008.
127. Singh KK, Ayyasamy V, Owens KM, Koul MS and Vujcic M: Mutations in mitochondrial DNA polymerase-gamma promote breast tumorigenesis. J Hum Genet 54: 516-524, 2009.
128. Coucke PA, Li YX, Copaceanu ML, et al: Cell line specific radiosensitizing effect of zalcitabine (2′,3′-dideoxycytidine). Acta Oncol 36: 199-205, 1997.
129. Humer J, Ferko B, Waltenberger A, Rapberger R, Pehamberger H and Muster T: Azidothymidine inhibits melanoma cell growth in vitro and in vivo. Melanoma Res 18: 314-321, 2008.
130. De Napoli L, Lacovino R, Messere A, et al: Synthesis of platinum(II) complexes of thymidine and 1-methylthymine (1-MeThy); crystal structure of cis-[PtCl(1-MeThy)(PPh3)2]. J Chem Soc Dalton Trans 1999: 1945-1950, 1999.
131. Besson C, Panelatti G, Delaunay C, et al: Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide. Leuk Lymphoma 43: 2275-2279, 2002.
132. Levine AM, Tulpule A, Espina B, et al: Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time. Cancer 78: 517-526, 1996.
133. Modica-Napolitano JS, Koya K, Weisberg E, Brunelli BT, Li Y and Chen LB: Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077. Cancer Res 56: 544-550, 1996.
134. Nguyen DM and Hussain M: The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies. J Bioenerg Biomembr 39: 13-21, 2007.
135. Yen HC, Tang YC, Chen FY, Chen SW and Majima HJ: Enhancement of cisplatin-induced apoptosis and caspase 3 activation by depletion of mitochondrial DNA in a human osteosarcoma cell line. Ann NY Acad Sci 1042: 516-522, 2005.
136. Cummings BS and Schnellmann RG: Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 302: 8-17, 2002.
137. Schwerdt G, Freudinger R, Schuster C, Weber F, Thews O and Gekle M: Cisplatin-induced apoptosis is enhanced by hypoxia and by inhibition of mitochondria in renal collecting duct cells. Toxicol Sci 85: 735-742, 2005. (Pubitemid 40614304)
138. Troyano A, Fernandez C, Sancho P, de Blas E and Aller P: Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation. J Biol Chem 276: 47107-47115, 2001.
139. Kharbangar A, Khynriam D and Prasad SB: Effect of cisplatin on mitochondrial protein, glutathione, and succinate dehydrogenase in Dalton lymphoma-bearing mice. Cell Biol Toxicol 16: 363-373, 2000.
140. Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z and Cullen KJ: Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res 12: 5817-5825, 2006.
141. Lee MS, Kim JY and Park SY: Resistance of rho(0) cells against apoptosis. Ann NY Acad Sci 1011: 146-153, 2004.
142. Singh KK, Russell J, Sigala B, Zhang Y, Williams J and Keshav KF: Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene 18: 6641-6646, 1999.
143. Mizutani S, Miyato Y, Shidara Y, et al: Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs. Cancer Sci 100: 1680-1687, 2009.
144. Mizumachi T, Suzuki S, Naito A, et al: Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells. Oncogene 27: 831-838, 2008.
145. Kessel D and Sun HH: Enhanced responsiveness to photo-dynamic therapy-induced apoptosis after mitochondrial DNA depletion. Photochem Photobiol 70: 937-940, 1999.
146. Morgan J, Potter WR and Oseroff AR: Comparison of photo-dynamic targets in a carcinoma cell line and its mitochondrial DNA-deficient derivative. Photochem Photobiol 71: 747-757, 2000.
147. Hirama M, Isonishi S, Yasuda M and Ishikawa H: Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells. Oncol Rep 16: 997-1002, 2006.
148. Cullen KJ, Yang Z, Schumaker L and Guo Z: Mitochondria as a critical target of the chemotherapeutic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 39: 43-50, 2007.
149. Wallace KB and Starkov AA: Mitochondrial targets of drug toxicity. Annu Rev Pharmacol Toxicol 40: 353-388, 2000.
150. Levitt ML and Koty PP: Tyrosine kinase inhibitors in preclinical development. Invest New Drugs 17: 213-226, 1999.
151. Lee HC, Yin PH, Lin JC, et al: Mitochondrial genome instability and mtDNA depletion in human cancers. Ann NY Acad Sci 1042: 109-122, 2005.
152. Xie CH, Naito A, Mizumachi T, et al: Mitochondrial regulation of cancer associated nuclear DNA methylation. Biochem Biophys Res Commun 364: 656-661, 2007.
153. Sun Y, Lin H, Zhu Y, Ma C, Ye J and Luo J: Induction or suppression of expression of cytochrome C oxidase subunit II by heregulin beta 1 in human mammary epithelial cells is dependent on the levels of ErbB2 expression. J Cell Physiol 192: 225-233, 2002.
154. Lin PC, Lin JK, Yang SH, Wang HS, Li AF and Chang SC: Expression of beta-F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study. Int J Colorectal Dis 23: 1223-1232, 2008.
155. Verlaet M, Duyckaerts C, Rahmouni S, et al: Transient modifications of respiratory capacity in thymic cells during murine radioleukemogenesis. Free Radic Biol Med 33: 76-82, 2002.
156. Dement GA, Maloney SC and Reeves R: Nuclear HMGA1 nonhistone chromatin proteins directly influence mitochondrial transcription, maintenance, and function. Exp Cell Res 313: 77-87, 2007.
157. Wu CW, Yin PH, Hung WY, et al: Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer 44: 19-28, 2005.
158. Hehlgans S, Haase M and Cordes N: Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775: 163-180, 2007.
159. Harradine KA and Akhurst RJ: Mutations of TGFbeta signaling molecules in human disease. Ann Med 38: 403-414, 2006.
160. Marin-Hernandez A, Gracia-Mora I, Ruiz-Ramirez L and Moreno-Sanchez R: Toxic effects of copper-based antineoplastic drugs (Casiopeinas) on mitochondrial functions. Biochem Pharmacol 65: 1979-1989, 2003.
161. Preston T and Singh G: Mitochondrial signaling and cancer. Adv Cell Ageing Gerontol 7: 103-130, 2001.
162. Teo JW, Thayalan P, Beer D, et al: Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob Agents Chemother 50: 3665-3673, 2006.
163. Sun SY, Hail N Jr and Lotan R: Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 96: 662-672, 2004. (Pubitemid 38660229)
164. Hail N Jr: Mitochondria: A novel target for the chemo-prevention of cancer. Apoptosis 10: 687-705, 2005.
165. Hail N Jr and Lotan R: Cancer chemoprevention and mitochondria: targeting apoptosis in transformed cells via the disruption of mitochondrial bioenergetics/redox state. Mol Nutr Food Res 53: 49-67, 2009.
166. Petit T, Izbicka E, Lawrence RA, Nalin C, Weitman SD and Von Hoff DD: Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming units. Anticancer Drugs 10: 309-315, 1999.
167. Liminga G, Jonsson B, Nygren P and Larsson R: On the mechanism underlying calcein-induced cytotoxicity. Eur J Pharmacol 383: 321-329, 1999.
168. Joshi B, Li L, Taffe BG, et al: Apoptosis induction by a novel anti-prostate cancer compound, BMD188 (a fatty acid-containing hydroxamic acid), requires the mitochondrial respiratory chain. Cancer Res 59: 4343-4355, 1999.
169. Fantin VR, Berardi MJ, Scorrano L, Korsmeyer SJ and Leder P: A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell 2: 29-42, 2002.
170. Fulda S and Kroemer G: Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today 14: 885-890, 2009.
171. Gogvadze V, Orrenius S and Zhivotovsky B: Mitochondria as targets for chemotherapy. Apoptosis 14: 624-640, 2009.